A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction

Overview

The purpose of this study is to evaluate the safety and effectiveness of the study drug, taken once daily, known as tadalafil in Chinese participants with erectile dysfunction (ED). The study will last about up to 25 months for each participant.

Full Title of Study: “Postmarketing Surveillance Study: A Randomized, Open-Label, 3-Month Interventional Study of Tadalafil Effectiveness (2.5 mg and 5 mg) and Long-Term Safety Administered Once Daily in Chinese Men With Erectile Dysfunction”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2016

Interventions

  • Drug: Tadalafil
    • Administered orally

Arms, Groups and Cohorts

  • Experimental: 2.5 mg/5 mg tadalafil
    • 2.5 mg tadalafil orally once daily for 3 months (Period 1) and then 5 mg tadalafil orally once daily for 21 months (Period 2).
  • Experimental: 5 mg tadalafil
    • 5 mg tadalafil orally once daily for 24 months (Period 1 and Period 2).

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (Serious or Non-Serious)
    • Time Frame: Baseline through Month 12
    • A Treatment Emergent Adverse Event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline, regardless of causality or severity. The percentage of participants with TEAEs was calculated by dividing the number of participants with at least 1 TEAE over the 12-Month treatment period by the total number of participants analyzed, multiplied by 100%. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
  • Percentage of Participants Experiencing at Least One Adverse Event Leading to Discontinuation
    • Time Frame: Baseline through Month 12
    • Data presented are the number of participants who experienced 1 or more AEs (all causalities and drug-related) and serious AEs (SAEs) that lead to discontinuation. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Secondary Measures

  • Change From Baseline in the International Index of Erectile Function- Erectile Function (IIEF-EF) Domain Questionnaire Score
    • Time Frame: Baseline, Month 1; Baseline, Month 3
    • IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) mean of the change from baseline is from Mixed effect Model Repeat Measurement (MMRM) model. The model included covariates baseline + visit + pooled investigator + baseline*visit, where participant is a random effect.
  • Change From Baseline in the IIEF-EF Domain Questionnaire Score of 5 mg Tadalafil Treatments
    • Time Frame: Baseline, Month 6; Baseline, Month 12;Baseline, Month 18; Baseline, Month 24
    • IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) mean of the change from baseline is from Mixed effect Model Repeat Measurement (MMRM) model. The model included covariates baseline + visit + pooled investigator + baseline*visit, where participant is a random effect.
  • Percentage of Participants With “Yes” Responses to Sexual Encounter Profile (SEP) Diary
    • Time Frame: Month 1, Month 3
    • Participant-assessed diary has 5 questions(QI-Q5): 4 of the 5 questions were analyzed. Q2: successful penetration, Q3: successful intercourse, Q4: satisfied with erection, and Q5: satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1-Q5 scores were determined as the percentage of ‘Yes’ responses to each of the 5 questions out of all sexual attempts recorded during the time period.
  • Percentage of Participants Achieving Normal Erectile Functioning
    • Time Frame: Month 1, Month 3
    • Participants achieving a normal erectile functioning (defined as having an IIEF-EF Domain score of >=26) at Month 1 and Month 3.
  • Percentage of Participants Achieving Normal Erectile Functioning of 5 mg Tadalafil Treatments
    • Time Frame: Month 6, Month 12, Month 18, Month 24
    • Participants achieving a normal erectile functioning (defined as having an IIEF-EF Domain score of >=26) at Month 6 and Month 12.
  • Percentage of Participants With “Yes” Responses to Global Assessment Questions (GAQ)1 and GAQ2
    • Time Frame: Month 3, Month12, Month 24
    • Participants with “yes” responses to GAQ Question 1 (GAQ1) and GAQ Question 2 (GAQ2) of the GAQ questionnaire at Month 3 and Month 12. GAQ1: Has the treatment you have been taking during this study improved your erections? GAQ2: If yes, has the treatment improved your ability to engage in sexual activity?

Participating in This Clinical Trial

Inclusion Criteria

  • Have a history of erectile dysfunction for at least 3 months. – Are sexually active and willing to remain sexually active with the same female partner during the study. – Are willing to have 4 or more attempts of sexual intercourse with female partner between screening and first treatment start day. – Are willing to stay away from any other medicines that the participants were already taking for erectile dysfunction during this study period. Exclusion Criteria:

  • Have erectile dysfunction, which is caused by any other primary sexual disorder. – Have certain problems with kidneys, liver, heart, blood sugar levels, eyes, or central nervous system (study doctor will discuss with participants). – Have a penis deformity or penile implant that in the opinion of the participants' doctor is significant. – Have human immunodeficiency virus (HIV) infection. – Are using certain kinds of medicines, which are not allowed in this study. – Are allergic to tadalafil. – Are planning to father a baby or are in a relationship with a pregnant partner. – Are participating or discontinued participation in the past 30 days from any another clinical trial, which is not compatible with this trial. – Have participated or discontinued from any other tadalafil clinical trial. – Have a history of drug, alcohol, or substance abuse within the past 6 months.

Gender Eligibility: Male

Minimum Age: 22 Years

Maximum Age: 69 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Eli Lilly and Company
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon – Fri 9 AM – 5 PM Eastern time (UTC/GMT – 5 hours, EST), Study Director, Eli Lilly and Company

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.